Reclast (Zoledronic Acid) Regulatory Status: US, EU, Canada, UK Approval History

Zoledronic acid 5 mg by IV infusion (marketed as Reclast in the United States and as Aclasta in the European Union, Canada, and the United Kingdom) is approved in all four jurisdictions for postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, and Paget disease of bone. It is a nitrogen-containing bisphosphonate given once yearly for osteoporosis or as a single dose for Paget disease. This is a distinct product from Zometa (zoledronic acid 4 mg), which is approved separately for oncology-related bone disease and dosed monthly. Regulatory status can change; readers who need a current, legally reliable approval date or label wording should check the FDA's Drugs@FDA database or the equivalent EMA, Health Canada, or MHRA product page directly, since some dates and figures below have not been independently re-verified against primary regulatory documents for this draft.

What is established, what is not

Established: Zoledronic acid 5 mg IV is an approved treatment for postmenopausal osteoporosis, male osteoporosis, glucocorticoid-induced osteoporosis, and Paget disease of bone in the US, EU, Canada, and UK, and generic versions exist alongside the branded products in each of these markets. The drug's mechanism (bisphosphonate binding to bone mineral, uptake by osteoclasts, inhibition of the mevalonate pathway enzyme farnesyl pyrophosphate synthase) is well described in the bisphosphonate pharmacology literature and is not in dispute.

Plausible but requiring verification for any specific claim: The exact calendar dates of first approval and indication-by-indication expansion in each country, the precise numeric effect sizes from the HORIZON trials (vertebral and hip fracture risk reduction, mortality reduction after hip fracture), and any quoted guideline language attributed to specific bodies (NICE, Osteoporosis Canada, the ADA). These figures are commonly repeated in secondary sources, but the citations that would normally support them could not be confirmed against a verified primary source for this draft, so they should be treated as needing a check against the original trial publication or current label before being used in a clinical or regulatory context.

Not established from the material available here: Any comparison of real-world prescribing share, specific reimbursement pricing, or country-level guideline wording beyond what a reader can verify directly on the regulator's or guideline body's own site.

Is Reclast the same drug as Aclasta, and is it the same as Zometa?

Reclast and Aclasta contain the same active ingredient, the same 5 mg/100 mL concentration, and are used for the same metabolic bone disease indications; the difference is branding by region (Reclast in the US, Aclasta elsewhere). Zometa is a separate product: zoledronic acid 4 mg/5 mL, approved for oncology indications such as hypercalcemia of malignancy and skeletal-related events in bone metastases, given roughly monthly rather than yearly. Because the two products share an active ingredient but differ in dose, indication, and schedule, mixing them up is a recognized medication-safety hazard, and pharmacists and prescribers verifying an order should confirm which product and dose is intended before infusion.

United States: FDA approval

The FDA approved the 5 mg zoledronic acid formulation for postmenopausal osteoporosis, with additional approvals reported in subsequent years covering glucocorticoid-induced osteoporosis, Paget disease, osteoporosis prevention, and male osteoporosis. A 4 mg formulation for oncology use (Zometa) was approved separately and earlier. For a specific approval date, indication wording, or current label, the authoritative source is the FDA's own Drugs@FDA database, which readers should consult directly rather than relying on secondary summaries, since exact dates have not been independently confirmed for this draft.

Clinical practice guidelines from US endocrinology and bone-health societies generally list IV zoledronic acid as one of several first-line pharmacologic options for patients at high fracture risk, alongside oral bisphosphonates and other classes such as denosumab. The specific guideline text and year should be checked against the current published guideline rather than assumed from this summary.

Generic zoledronic acid 5 mg infusion products are available in the US from multiple manufacturers following patent expiry, and these are commonly administered in outpatient infusion centers or physician offices rather than dispensed as a take-home prescription.

European Union: EMA centralized authorization

Aclasta received centralized marketing authorization from the EMA, which means a single approval applies across all EU member states rather than country-by-country filings. The authorization covers osteoporosis in postmenopausal women and men at increased fracture risk (including after a recent low-trauma hip fracture), osteoporosis associated with long-term systemic glucocorticoid therapy, and Paget disease of bone. The EU product information requires assessment of renal function before each infusion, with a contraindication below a specified creatinine clearance threshold; the exact threshold and full contraindication list should be read from the current Aclasta Summary of Product Characteristics rather than assumed.

The EMA's pharmacovigilance processes have reviewed bisphosphonate-class safety signals, including atypical femoral fracture and osteonecrosis of the jaw, as part of ongoing benefit-risk monitoring for approved indications. Readers wanting the current safety communication should check the EMA's public assessment reports rather than a secondary summary.

Canada: Health Canada authorization

Health Canada has authorized Aclasta (zoledronic acid 5 mg/100 mL) for Paget disease and, separately, for osteoporosis indications that broadly mirror the EU label: postmenopausal osteoporosis, male osteoporosis, and glucocorticoid-induced osteoporosis. The Canadian product monograph is reported to require pre-infusion serum creatinine measurement, adequate hydration, and calcium/vitamin D supplementation, consistent with the renal and mineral-safety precautions used in other jurisdictions; the current monograph on Health Canada's Drug Product Database is the authoritative source for exact wording.

Claims about Canadian prescribing trends (for example, changes in the share of new bisphosphonate starts that use IV zoledronic acid) and any quoted Osteoporosis Canada guideline language have been removed from this draft because the underlying source could not be verified. A reader interested in current Canadian prescribing patterns or guideline wording should consult Osteoporosis Canada's published guideline directly.

Generic zoledronic acid formulations are listed on Canadian provincial formularies alongside branded Aclasta, and provincial drug plans generally favor the lower-cost generic where available, though specific pricing varies by province and over time.

United Kingdom: MHRA and NICE

Aclasta was available in the UK under the EMA centralized authorization, and following Brexit the MHRA converted the existing EU authorization into a UK marketing authorization, so the drug remains approved in the UK for the indications listed above. NICE guidance on osteoporosis management generally positions oral alendronate as a first-line option, with alternatives such as oral risedronate or IV zoledronic acid considered when alendronate is contraindicated or not tolerated. The exact wording of the current NICE guideline should be read on NICE's own site, since a specific quoted passage in an earlier version of this article could not be confirmed against the primary guideline document and has been removed here.

Claims about the specific share of UK bisphosphonate prescriptions accounted for by zoledronic acid, and any year-over-year prescribing trend, have also been removed pending verification against a named, checkable data source (for example, OpenPrescribing's own published figures for a stated date range).

What the pivotal trials are reported to show

Two large randomized trials, generally referred to as HORIZON-PFT (in postmenopausal women with osteoporosis) and HORIZON-RFT (in patients following surgical repair of a low-trauma hip fracture), are widely cited as the clinical evidence base for the osteoporosis and post-fracture indications across these jurisdictions. HORIZON-PFT is commonly reported to have shown a substantial reduction in vertebral fracture risk and a smaller but still significant reduction in hip fracture risk with annual IV zoledronic acid compared with placebo over three years. HORIZON-RFT is commonly reported to have shown a reduction in new clinical fractures and, notably, a reduction in all-cause mortality in the zoledronic acid group, a finding that is unusual among osteoporosis trials.

These trial results are treated in this draft as generally reported findings rather than independently re-verified numbers. A reader who needs the exact percentage reductions, confidence intervals, or p-values for clinical decision-making or citation should pull the original New England Journal of Medicine publications for HORIZON-PFT and HORIZON-RFT rather than rely on this summary, since the specific PubMed identifiers previously attached to these claims could not be confirmed to be correct.

For Paget disease, single-infusion zoledronic acid is generally reported to produce a higher rate of biochemical response (normalization or near-normalization of serum alkaline phosphatase) than a course of oral risedronate, which is consistent with why Paget disease was the first indication approved in several of these markets. Exact response rates should again be checked against the original trial report.

Safety patterns reflected across all four labels

Renal function assessment before each infusion, and a contraindication below a specified creatinine clearance, appears in the labeling of all four jurisdictions, reflecting the drug's renal clearance and the risk of acute kidney injury with rapid infusion or in patients with impaired renal function. Acute-phase reactions, fever, myalgia, arthralgia, and headache in the days following infusion, are a recognized and common short-term effect, generally most frequent after the first dose and less frequent with subsequent annual infusions.

Atypical femoral fracture and osteonecrosis of the jaw are class-effect warnings that apply to zoledronic acid along with other bisphosphonates. Both are described in the literature as rare in the osteoporosis-dose population, with risk reported to increase with longer cumulative bisphosphonate exposure, though exact incidence figures vary by study population and should be sourced from a current systematic review or regulatory safety communication rather than a single number repeated without a checkable citation. All four regulators recommend dental evaluation before starting bisphosphonate therapy in patients who have risk factors for osteonecrosis of the jaw, such as planned invasive dental work, cancer treatment, or concurrent corticosteroid use; this is a precaution based on risk factors, not a requirement that applies identically to every patient starting the drug.

Pregnant and breastfeeding women, and patients with hypocalcemia or known bisphosphonate hypersensitivity, are generally excluded from treatment; anyone considering zoledronic acid for osteoporosis or Paget disease should confirm contraindications with the prescriber against their own kidney function, calcium status, and dental history rather than relying on a general summary.

Generic availability and cost

Zoledronic acid's original composition-of-matter patent has expired, and generic 5 mg infusion products are marketed in the US, EU, Canada, and UK by more than one manufacturer. Because the drug is typically administered in a clinic or infusion center rather than dispensed at a retail pharmacy, the relevant cost for most patients is the facility and infusion charge plus the drug cost, and this varies by country, payer, and site of care in ways that are not captured by a single global price figure. Readers who need a current price or reimbursement rate should check with their own payer (for example, a Medicare Part B explanation of benefits in the US, or the relevant provincial or NHS formulary elsewhere) rather than rely on a figure quoted without a date.

Verification checklist before relying on a regulatory or trial claim about zoledronic acid

Because this topic mixes four separate national regulatory histories with trial statistics that are easy to misattribute, use this sequence before treating any specific number or approval date as fact:

If a claim fails this checklist, the safer default for an editor or clinician is to state the general, well-supported fact (for example, "zoledronic acid is approved for osteoporosis in this country") and omit the specific number rather than risk repeating an unverified figure.

When to seek care rather than rely on this summary

This article describes regulatory history and general safety patterns; it is not a substitute for an individualized recommendation. Anyone who develops severe bone, joint, or muscle pain, jaw pain or numbness, unusual thigh or groin pain, or signs of an allergic reaction after a zoledronic acid infusion should contact the prescribing clinic or seek urgent care rather than wait for a routine follow-up. Questions about whether zoledronic acid, an oral bisphosphonate, or a non-bisphosphonate alternative such as denosumab is the right choice for a specific patient depend on kidney function, fracture risk, ability to tolerate oral dosing, and other individual factors that only a treating clinician can weigh.

This article summarizes publicly reported regulatory history and general bisphosphonate safety information for education. Several precise dates, trial statistics, and quoted guideline passages present in an earlier version of this page could not be verified against a confirmed primary source and have been removed or narrowed; readers who need exact figures for clinical, legal, or regulatory purposes should confirm them directly with the FDA, EMA, Health Canada, or MHRA, or with the original trial publication. This article does not provide individualized diagnosis or dosing advice.